Intelligent Antibody Discovery

Corporate Overview

Business Overview

Abeome is a privately-held discovery stage biotechnology company focused on the high-throughput selection, analysis, and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales.

Business Strategy

Abeome utilizes its AbeoMouseTM technology internally, facilitating the revelation of the most advanced mAb drug candidates with unprecedented speed and specificity. Additionally, Abeome is establishing partnerships with biotechnology and pharmaceutical companies around the world to exploit the AbeoMouseTM platform.

Product Strategy

Focus on drug targets of known high value where AbeoMouseTM enables the discovery of antibodies with BioBetter properties and freedom to operate. Novel/Intractable target partnerships are also of interest.

Intellectual Property

Abeome’s platform technology is covered by three US patents: 2 issued, 1 pending.

Management Team

Abeome has a strong management team with deep scientific and clinical resources and extensive experience with the commercialization of biological intellectual property.

Corporate Milestones

  • 2000 – founded from University of Georgia technology
  • 2002 – launched laboratory operations in Athens, GA
  • 2000-2008 – DiSHTM technology development and commercialization
  • 2009-Present – AbeoMouseTM transgenic mouse system developed

Board of Directors

Kirby Alton, PhD.

Kirby was one of the original Amgen scientists (1981) and from 1983 through his retirement in 1999 was head of Amgen product development serving as Senior Vice President. During this time, Amgen discovered and brought its first products to market, Epogen and Neupogen. Dr. Alton had responsibility for global Pre-clinical Research, Clinical Development and Regulatory Affairs, serving as the company’s Responsible Head and on the Executive Operating Committee. Dr. Alton is also a member of the Board of Directors of the University of Georgia Research Foundation.

Richard Shimkets, PhD.

Richard Shimkets, PhD., was previously the VP of Drug Discovery and VP of Scientific Development for CuraGen Corporation, a biotechnology company focused on monoclonal antibody discovery which was founded by research faculty of the Yale University Genetics Department.

Christopher McLeod

Christopher McLeod is an experienced biotechnology executive, formerly serving as Executive Vice President of CuraGen Corporation and then President of 454 Life Sciences, which was acquired by Roche Diagnostics in 2007. Mr. McLeod is the managing parter of Elm Street Ventures.

Marty Simonetti

Marty is a pharmaceutical company executive with significant experiment at Amgen and Genentech. Marty serves on the Board of Nexgenia, VLST and Curtana Pharmaceuticals, and served as CFO of Dendreon, Kirin-Amgen and Amgen Biopharma.

James E. Pitts III

James E. Pitts III has a long career in real estate development and is currently owner and President of real estate development entities Randcor, Inc. and Randcor Management Inc. of Atlantic Beach, Florida.

Lewis Scruggs

Lewis Scruggs is CEO of A I Insurance Group in Watkinsville, GA and serves as the company’s Treasurer.

Paul Steinfeld

Paul Steinfeld is the former Chairman and CEO of Shelby Williams Industries (NYSE Company) and formerly served as Managing Director of Longbow Group LLC, a private investment management firm. In addition, Mr. Steinfeld is the Honorary Consul for the Republic of Slovenia.